Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioners National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology…